Non-COVID mRNA Therapeutics and Therapeutics Market Benefiting from Advances in Technology, Scalability, and Personalized Medicine Approaches for Disease Prevention

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Non-covid mRNA Vaccine and Therapeutics Market Size, Share & Trends Analysis Report By Product Type (mRNA Therapeutic, mRNA Vaccines), By Therapeutic Area (Infectious Diseases, Oncological Disorders, Other Disorders), By Route of Administration (Intravenous, Intramuscular, Intranasal, Others)- Market Outlook and Industry Analysis 2031"

The Global Non-covid mRNA Vaccine and Therapeutics Market is valued at US$ 370.0 Mn in 2024, and it is expected to reach US$ 1,684.80 Mn by 2031, with a CAGR of 24.20% during the forecast period of 2024-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2814

Advancements in mRNA technology for medical therapeutics and vaccines are progressing at an unprecedented rate, positioning the non-COVID mRNA vaccine and therapeutics market for substantial growth. This innovative approach utilizes synthetic mRNA to instruct cells to produce specific proteins, which can be leveraged for the treatment and prevention of a variety of diseases, including infectious diseases, cancers, and certain genetic disorders. Unlike traditional vaccines that weaken pathogens, mRNA vaccines direct cells within the human body to generate an immune response, offering a more flexible and rapid method of combating emerging health threats. This adaptability makes mRNA a highly versatile tool for both disease prevention and therapy.

The potential applications of non-COVID mRNA therapeutics are vast. mRNA vaccines are currently under development for a range of infectious diseases, including influenza, HIV, and Zika, to elicit robust immune responses. In the realm of oncology, mRNA vaccines targeting tumor-specific antigens are being designed to aid in the destruction of cancer cells, with personalized vaccines being developed based on individual tumor profiles. Furthermore, mRNA technology holds promise for addressing genetic disorders by providing cellular instructions to produce missing or malfunctioning proteins. The value of mRNA technology lies in its ability to accelerate production, enhance scalability, and demonstrate proven safety and efficacy, positioning it as a critical solution for addressing unmet medical needs across a wide array of therapeutic areas.

List of Prominent Players in the Non-covid mRNA Vaccine and Therapeutics Market:
• CureVac
• Anima Biotech
• Arcturus Therapeutics
• BioNTech (Pfizer)
• eFFECTOR Therapeutics, Inc.
• eTheRNA
• Ethris (AstraZeneca)
• H3 Biomedicine Inc. (Eisai Inc.)
• In-Cell-Art
• Ionis Pharmaceuticals, Inc.
• Kernal Biologics
• Moderna
• RNAimmune (Sirnaomics)
• Silence Therapeutics
• Skyhawk Therapeutics, Inc.
• Stemirna Therapeutics Co., Ltd.
• Tiba Biotechnology
• Translate Bio Sanofi)
• Ziphius Therapeutics NV

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04

Market Dynamics:
Drivers:
The non-COVID mRNA vaccine and therapeutics market is experiencing significant growth driven by advancements in technology, stability, delivery, and efficacy, with innovations such as lipid nanoparticles playing a critical role. The potential applications for mRNA-based treatments are vast, ranging from vaccines for infectious diseases to personalized therapies for cancer and treatments for genetic disorders. The scalability of mRNA production, demonstrated during the COVID-19 pandemic, ensures rapid, high-volume manufacturing. Moreover, the favorable safety profile of mRNA vaccines and the increased investment following the success of COVID-19 vaccines are propelling the market forward. Sanofi's acquisition of Translate Bio strengthens its mRNA Center of Excellence, further driving innovation across various therapeutic areas, including vaccines, immunology, oncology, and rare diseases.

Challenges:
Despite the market's potential, several challenges hinder the efficiency of production in the non-COVID mRNA vaccine and therapeutics space. Uncoordinated processes involving multiple vendors often result in inefficiencies and delays, particularly for smaller companies with limited resources. Furthermore, restricted access to GMP-grade raw materials creates bottlenecks that affect production timelines. The complexity of mRNA manufacturing, especially in ensuring the purification and contamination-free production of mRNA, presents significant challenges, making the process both time-consuming and difficult to manage effectively.

Regional Trends:
North America remains a key player in the non-COVID mRNA market, bolstered by its robust infrastructure in research and development, alongside leading pharmaceutical companies, biotech firms, and prominent academic institutions. This ecosystem fosters innovation and attracts significant investments and collaborations, as evidenced by Moderna's mRNA vaccine, mRESVIA, which has received U.S. FDA approval to protect adults aged 60 and older from severe RSV-related respiratory disease. Furthermore, the region benefits from substantial investments from both public and private sectors, supported by a regulatory environment that accelerates approval processes, positioning North America at the forefront of mRNA technology development.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2814

Recent Developments:
• In Jan 2023, Moderna, Inc. announced a definitive agreement to acquire OriCiro for $85 million. This acquisition provides Moderna with advanced tools for cell-free synthesis and amplification of plasmid DNA, a crucial component in the mRNA manufacturing process.
• In Aug 2021, Sanofi entered into a definitive agreement to acquire Translate Bio, a clinical-stage mRNA therapeutics company, for $38.00 per share in cash, totaling approximately $3.2 billion. Both companies' Boards of Directors have unanimously approved the transaction, aiming to accelerate Sanofi's development of mRNA-based therapeutics and vaccines.

Segmentation of Non-covid mRNA Vaccine and Therapeutics Market-
Non-covid mRNA Vaccine and Therapeutics Market- By Product Type
• mRNA Therapeutic
• mRNA Vaccines
Non-covid mRNA Vaccine and Therapeutics Market- By Therapeutic Area
• Infectious Diseases
o Influenza
o Respiratory Syncytial Virus (RSV)
o Cytomegalovirus
o Others
• Oncological Disorders
• Other Disorders
Non-covid mRNA Vaccine and Therapeutics Market- By Route of Administration
• Intravenous
• Intramuscular
• Intranasal
• Others
Non-covid mRNA Vaccine and Therapeutics Market- By Region
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/non-covid-mrna-vaccine-and-therapeutics-market/2814

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.